# Neomed Management

> Neomed Management is a VC fund in Oslo backing Health Care and Biotechnology. See 41 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oslo, Norway
- Total investments: 41
- Last investment: Mar 2021
- Lead investor: 15%
- Last updated: Aug 2026
- Website: http://neomed.net

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

## Contacts

5 contacts available for Neomed Management. Shizune tracks 7 team members at Neomed Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/neomed-management?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8.3M–$37M |
| Series B | $20M–$65M |
| Series C | $10M–$44M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 16 | 39% |
| Biotechnology | 16 | 39% |
| Medical | 9 | 22% |
| Medical Device | 7 | 17% |
| Pharmaceutical | 5 | 12% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 22% |
| Series C | 8 | 20% |
| Series A | 5 | 12% |
| Funding Round | 5 | 12% |
| Post-IPO Equity | 3 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 8 | 20% |
| United States | 6 | 15% |
| Italy | 1 | 2% |
| France | 1 | 2% |
| Norway | 1 | 2% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Erik Amble | Founder, Chairman & Managing Partner | 11 | https://shizune.co/investors/profile/erik-amble-8d03 |
| Thomas Goebel | Principal | 2 | https://shizune.co/investors/profile/thomas-goebel |
| Vincent Ossipow | Partner | 5 | https://shizune.co/investors/profile/vincent-ossipow |
| Claudio Nessi | Partner | 16 | https://shizune.co/investors/profile/claudio-nessi |
| Line B. Westlund | Office Manager | 0 | https://shizune.co/investors/profile/line-b-westlund |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Oxular | Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. | $37M |  | Mar 01, 2021 |  |
| Oxular | Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. | $37M | Series B | Mar 01, 2021 |  |
| JenaValve Technology | JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M | Venture - Series Unknown | Feb 05, 2020 |  |
| Sonendo | Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $85M |  | Jan 06, 2020 |  |
| Sequana Medical | Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $9.3M | Series D | Oct 16, 2018 |  |
| Avitide | Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions.The company was founded in 2012 andis based in Lebanon, New Hampshire. | $12M | Series E | Jun 21, 2017 |  |
| Axonics Modulation Technologies | Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $14.5M | Series C | May 02, 2017 |  |
| Sonendo | Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $35M | Series E | Dec 13, 2016 |  |
| Axonics Modulation Technologies | Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $38.5M | Series B | Dec 22, 2015 |  |
| Sequana Medical | Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $10.5M | Series C | Oct 23, 2015 |  |

10 of 41 investments shown.

## Co-investors
- [VI Partners](https://shizune.co/investors/profile/vi-partners) — VC Fund, 14 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 10 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 8 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Health Care Investors in Switzerland](https://shizune.co/investors/health-care-investors-switzerland)
- [Health Care VC Funds in Switzerland](https://shizune.co/investors/health-care-vc-funds-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)

## FAQ

### What does Neomed Management invest in?

Neomed Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 41 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Neomed Management's check size?

Neomed Management typically joins rounds of $8.3M–$37M at Series A, $20M–$65M at Series B and $10M–$44M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Neomed Management participates in.

### How do I contact Neomed Management?

Public channels for Neomed Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Neomed Management?

The team at Neomed Management includes Erik Amble (Founder, Chairman & Managing Partner), Thomas Goebel (Principal) and Vincent Ossipow (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co